ACS

Latest Features

Benefits of Inpatient Smoking Cessation Therapy Post-Myocardial Infarction

Benefits of Inpatient Smoking Cessation Therapy Post-Myocardial Infarction

Hospitals may be missing opportunities to start tobacco use treatment immediately after myocardial infarction.

Cardiac Rehabilitation: Changes, Challenges, and Clinician Perspectives

Cardiac Rehabilitation: Changes, Challenges, and Clinician Perspectives

An overview of cardiac rehabilitation use plus interviews with Monica Mukherjee, MD, MPH, FACC, FASE and with Jonathan Ledyard, MS, RCEP.

Assessing Chest Pain in ER With Short-term Risk Stratification Tool

Assessing Chest Pain in ER With Short-term Risk Stratification Tool

The HEART Score is a safe risk-stratification tool for chest pain, but it does not seem to do much for reducing hospital utilization and admissions.

Oxygen Therapy for Acute MI: Best Practice or Harmful Treatment?

Oxygen Therapy for Acute MI: Best Practice or Harmful Treatment?

Evidence is lacking to support oxygen therapy for acute myocardial infarction.

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Bioresorbable Stents Promising But Metal Stents Still Have Role in Coronary Intervention

Bioresorbable Stents Promising But Metal Stents Still Have Role in Coronary Intervention

Experts say bioresorbable stents are "a few generations away" from being standard of care in interventional cardiology.

Deferred Stenting or Ischemic Postconditioning in STEMI Patients Did Not Reduce Adverse Events

Deferred Stenting or Ischemic Postconditioning in STEMI Patients Did Not Reduce Adverse Events

A composite end point of death, heart failure, new myocardial infarction, and revascularization was similar between the deferred stenting group and the conventional treatment group.

Room for Improvement: Pharmacologic Management of Acute Coronary Syndromes

Room for Improvement: Pharmacologic Management of Acute Coronary Syndromes

Poor adherence to dual antiplatelet therapy plays a significant role in outcomes for patients with acute coronary syndromes.

Risk of Cardiovascular Disease Questioned in Testosterone Therapy Use

Risk of Cardiovascular Disease Questioned in Testosterone Therapy Use

The American Association of Clinical Endocrinologists site lack of evidence of cardiovascular disease risk in testosterone therapy use.

Latest News

Coronary Artery Disease, MI Risk With Abacavir-containing ART

Coronary Artery Disease, MI Risk With Abacavir-containing ART

The researchers concluded abacavir-containg ART does not increase the risk of coronary artery disease or myocardial infarction

New ESC Guidelines Provide Insight into ST-Segment Elevation Management

New ESC Guidelines Provide Insight into ST-Segment Elevation Management

The European Society of Cardiology has released new guidelines regarding treatment strategies for acute myocardial infarction and STEMI.

Comparison of PCI Outcomes With Bivalirudin vs Heparin Post-STEMI or NSTEMI

Comparison of PCI Outcomes With Bivalirudin vs Heparin Post-STEMI or NSTEMI

In patients undergoing percutaneous coronary intervention for either STEMI or NSTEMI, bivalirudin and heparin produce similar outcomes.

Suspected MI: No Difference Between Supplemental Oxygen and Ambient Air Treatment

Suspected MI: No Difference Between Supplemental Oxygen and Ambient Air Treatment

Supplemental oxygen therapy does not decrease the risk for 1-year all-cause mortality in patients with suspected myocardial infarction.

Atherosclerotic Disease Benefits From Interleukin-1β Targeting

Atherosclerotic Disease Benefits From Interleukin-1β Targeting

In high-risk patients with atherosclerotic disease, canakinumab may help reduce the incidence of cardiovascular events.

Early vs Delayed Invasive Strategy in Non-ST-Elevation Acute Coronary Syndromes

Early vs Delayed Invasive Strategy in Non-ST-Elevation Acute Coronary Syndromes

In patients with non-ST-elevation acute coronary syndromes, an early invasive treatment strategy does not significantly reduce mortality rates.

Elevated High-Sensitivity Troponin T in Afib May Not Increase Coronary Event Risk

Elevated High-Sensitivity Troponin T in Afib May Not Increase Coronary Event Risk

Patients with atrial fibrillation but without known coronary artery disease may not be at an increased risk for coronary events, despite elevated high-sensitivity troponin T levels.

Can Beta-Blockers Reduce Mortality in Acute Myocardial Infarction Without Heart Failure?

Can Beta-Blockers Reduce Mortality in Acute Myocardial Infarction Without Heart Failure?

In patients with acute myocardial infarction without heart failure, beta-blockers did not reduce mortality risk at 1 year.

Chronic Angina Therapy Gets Fast Track Designation From FDA

Chronic Angina Therapy Gets Fast Track Designation From FDA

XyloCor's XC001 is a potential therapy for patients with chronic angina.

Single High-Sensitivity Cardiac Troponin T Measurement Could Rule Out Acute Myocardial Infarction

Single High-Sensitivity Cardiac Troponin T Measurement Could Rule Out Acute Myocardial Infarction

Sensitivity of the acute myocardial infarction risk classification ranged from 87.5% to 100%, and the pooled sensitivity estimate was 98.7%.